Can zaleplon (zapleon) and temazepam (Restoril) be administered together?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Do Not Combine Zaleplon and Temazepam

You should not give zaleplon (Sonata) and temazepam (Restoril) together. Both are sedative-hypnotics that act on GABA receptors and combining them significantly increases the risk of excessive CNS depression, respiratory depression, oversedation, falls, and complex sleep behaviors.

Why This Combination Is Dangerous

Overlapping Mechanisms and Additive CNS Depression

Both medications work through GABAergic mechanisms:

  • Zaleplon: Non-benzodiazepine hypnotic (Z-drug) that binds preferentially to α1β2γ2 GABA-A receptor subunits 1
  • Temazepam: Benzodiazepine that acts on GABA-A receptors

The FDA label for Restoril explicitly warns: "If Restoril is to be combined with other drugs having known hypnotic properties or CNS-depressant effects, consideration should be given to potential additive effects" 2. This is not a suggestion to proceed cautiously—it's a warning that additive effects are expected and dangerous.

Specific Risks of Combination

The combination creates compounded risks:

  • Excessive sedation and respiratory depression: Both drugs depress CNS function; combining them multiplies this effect
  • Increased fall risk: Particularly dangerous in elderly patients, where temazepam alone already carries fall risk 3
  • Complex sleep behaviors: "Sleep-driving" and other dangerous behaviors are more likely when Restoril is combined with other CNS depressants 2
  • Cognitive and psychomotor impairment: Prolonged next-day effects become more likely
  • Synergistic toxicity: The FDA label specifically mentions synergistic effects with other sedatives 2

The Correct Approach: Choose One Agent

Selection Algorithm

For sleep-onset insomnia only:

  • Use zaleplon 10 mg (ultra-short half-life ~1 hour, minimal next-day effects) 4, 1
  • Alternative: temazepam 15 mg 4

For sleep-maintenance insomnia:

  • Use temazepam 15 mg (longer duration of action) 4, 5
  • Zaleplon is less effective for maintenance due to its short half-life 1

For both sleep-onset AND maintenance:

  • Use temazepam 15 mg as single agent 4
  • Do NOT add zaleplon to extend coverage

Evidence Supporting Single-Agent Therapy

The 2017 American Academy of Sleep Medicine guidelines recommend these agents as monotherapy alternatives, not as combination therapy 4. A direct comparison study showed temazepam provided "significantly longer and qualitatively better sleep than zaleplon" when each was used alone 5.

Common Pitfalls to Avoid

  1. Don't layer hypnotics: If one agent isn't working, switch to a different class (e.g., orexin antagonist, low-dose doxepin), don't add another GABA-ergic agent
  2. Don't assume "different classes" means safe combination: Z-drugs and benzodiazepines both work through GABA mechanisms
  3. Elderly patients are at highest risk: The combination dramatically increases fall risk, confusion, and oversedation in this population 2, 3
  4. Middle-of-night dosing concerns: Even if considering zaleplon for middle-of-night awakening while on temazepam—don't do it; the drugs will overlap

What to Do Instead

If a single hypnotic is inadequate:

  • First: Optimize the current agent's dose and timing
  • Second: Switch to a different mechanism (suvorexant, low-dose doxepin, ramelteon)
  • Third: Address underlying causes (sleep hygiene, cognitive behavioral therapy for insomnia)
  • Never: Combine two GABA-ergic hypnotics

The evidence is clear: these medications should be used as monotherapy alternatives, not in combination. The risk of serious adverse events—including potentially fatal respiratory depression—far outweighs any theoretical benefit of combining them.

Related Questions

What are the effects, mechanisms of action, and indications of zaleplon, temazepam, and zolpidem?
For an adult requiring short‑term treatment of insomnia, which medication is preferred: zaleplon, temazepam (Restoril), or zolpidem (Ambien)?
What is the appropriate management for a 55-year-old male who can fall asleep but cannot maintain sleep and experiences frequent movement during the night?
In a 64-year-old man with difficulty staying asleep and frequent awakenings, what medications are recommended for sleep‑maintenance insomnia?
A 63-year-old patient taking eszopiclone (Lunesta) 2 mg nightly continues to have difficulty falling asleep, frequent awakenings, and restlessness; what is the next step in management?
In a typical adult without significant comorbidities, which of the following hypnotic agents—Zaleplon, Temazepam (Restoril), Zolpidem (Ambien), Ramelteon, Eszopiclone (Lunesta), or Trazodone—is most appropriate for treating insomnia?
Is riociguat indicated for treatment of heart failure?
If a patient's serum creatinine rises from 1.0 mg/dL to 1.30 mg/dL, does this meet criteria for acute kidney injury and what immediate management steps are recommended?
Is it safe to combine evening primrose oil (EPO) and cod liver oil to improve skin health?
Which medication can be given with Restoril (temazepam) to improve sleep?
What is the appropriate spironolactone dose for a patient with heart failure with reduced ejection fraction and an estimated glomerular filtration rate of 28 mL/min?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.